Premier Bank Selects CSI for Strategic, Customer-Centric Core Banking Services

Premier Bank Selects CSI for Strategic, Customer-Centric Core Banking Services

PADUCAH, Ky.–(BUSINESS WIRE)–
Computer Services, Inc. (CSI) (OTCQX: CSVI), a provider of end-to-end fintech and regtech solutions, announced that Dubuque, Iowa-based Premier Bank ($390 million in assets) has selected its NuPoint® core platform in order to offer more strategic and reliable banking solutions that can evolve in lockstep with its customers.

Premier Bank began evaluating new core providers almost two years ago, but a recent COVID-19-related reliability issue on the digital side served as the impetus for the bank to make the switch to CSI.

“When the first round of COVID-19 relief came out, everyone tried to check their balances at once,” said Andrew Mozena, president and CEO of Premier Bank. “We were down for a solid week, with zero access for our customers. Communication and the ability to respond was extremely poor, and that was the straw that broke the camel’s back.”

Premier Bank was using an in-house core processing system that required the institution to have not only a considerable amount of extra hardware on site, but also the expertise to manage it themselves. Mozena said CSI’s private cloud environment will simplify the bank’s back room operations and alleviate its responsibility to configure important systems, like disaster recovery, on its own.

In addition to service and technology upgrades, Mozena said Premier Bank chose CSI due to the company’s philosophies on service and pricing.

“Once you’re a CSI customer, you’re a customer,” said Mozena. “That means as software changes and enhancements are made, they flow through to the bank. That was certainly not the case with our previous provider. We want to remain relevant as the communication between consumers and banks changes and evolves, and I think we have a much better chance of that with CSI.”

Premier Bank will also take advantage of CSI’s suite of digital banking solutions, which is fully integrated into the core platform. For the first time, Premier Bank will not depend on a third party to administer its debit card program, which means customers will have multiple convenient card options available to them through CSI’s mobile banking app.

“For the last 22 years, Premier Bank has built a solid reputation as an institution that is completely invested in its community and its customers,” said David Culbertson, CSI’s president and COO. “I am thrilled for the privilege to enter into a new technology partnership with Premier Bank, and I am confident that our dedication to service and innovation will help the bank exceed its goals for years to come.”

About Premier Bank

Since 1998, Premier Bank has served customers across the city of Dubuque, Iowa, with the financial resources, lending opportunities and digital banking solutions they need to thrive. Premier believes serving its customers extends to serving the community. The bank’s staff is involved with, and proud to support, numerous community organizations and events. For more information, visit www.premierbanking.bank.

About Computer Services, Inc.

Computer Services, Inc. (CSI) delivers innovative financial technology and regulatory compliance solutions to financial institutions and corporate customers across the nation. Through a combination of expert service, cutting-edge technology and a customer-first mentality, CSI excels at driving businesses forward in a rapidly changing industry. CSI’s expertise and commitment to authentic partnerships has resulted in the company’s inclusion in such top industry-wide rankings as the FinTech 100, American Banker’s Best Fintechs to Work For and MSPmentor Top 501 Global Managed Service Providers List. CSI’s stock is traded on OTCQX under the symbol CSVI. For more information about CSI, visit www.csiweb.com.

Laura Sewell

For CSI

270-349-9212

Haleigh Tomasek

For CSI

678-781-7208

KEYWORDS: Kentucky Iowa United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Technology Finance Software Banking

MEDIA:

Logo
Logo

Telenor Myanmar Taps Akamai for Subscriber Security

Network operator rolls out customer cyber security defenses using Akamai technology and threat intelligence

PR Newswire

CAMBRIDGE, Mass., Dec. 17, 2020 /PRNewswire/ — Akamai (NASDAQ: AKAM), the intelligent edge platform for securing and delivering digital experiences, today announced that Telenor Myanmar is using Akamai’s SPS Shield product to help protect subscribers from a host of cyber security threats. Available as Telenor Business Web Shield to Telenor Myanmar Business customers, the service automatically activates defenses against bots, malware, phishing and other types of attacks.

SPS Shield, part of Akamai’s Security and Personalization Services (SPS) portfolio of solutions for internet service providers (ISP) and mobile network operators (MNO), is a cloud-based security service designed for small- and mid-sized -businesses and residential subscribers. It is built as an entry-level, white-label offering for MNOs and ISPs that is extremely simple for them to deploy and onboard subscribers.

“Customer security and safety is a critical pillar of our business and essential to earning and keeping the trust of our subscribers,” said Caroline Yin Yin Htay, Chief Business Officer, Telenor Myanmar. “As the foundation of our Web Shield service, Akamai SPS Shield is a simple solution to the very complex challenge of keeping up with a threat landscape that is perpetually changing and evolving. It works seamlessly for the end user without the need to install software or change hardware, automatically protecting the devices connected to our network.”

SPS Shield runs on Akamai’s pervasive, highly distributed Intelligent Edge Platform. It is based on Akamai DNSi resolver and security infrastructure, which use real-time, AI-driven threat feeds developed by a hundreds-strong team of data scientists and security experts.

“Akamai is offering network operators a way to easily turn on revenue-generating, churn-reducing security capabilities without the need for customer intervention, much less a service call of any sort,” said Sid Pisharoti, Regional Vice President – APJ Media and Carrier, Akamai. “As a cloud-based solution, SPS Shield accelerates time to market and minimizes start-up investment while giving operators complete control over business models, pricing and branding.”

Web Shield is currently available to Telenor Myanmar Business mobile customers. Part of the Telenor Group, one of the world’s major mobile operators, Telenor Myanmar serves 17 million customers across all of the country’s states, regions and territories.

About Akamai
Akamai secures and delivers digital experiences for the world’s largest companies. Akamai’s intelligent edge platform surrounds everything, from the enterprise to the cloud, so customers and their businesses can be fast, smart, and secure. Top brands globally rely on Akamai to help them realize competitive advantage through agile solutions that extend the power of their multi-cloud architectures. Akamai keeps decisions, apps and experiences closer to users than anyone — and attacks and threats far away. Akamai’s portfolio of edge security, web and mobile performance, enterprise access and video delivery solutions is supported by unmatched customer service, analytics and 24/7/365 monitoring. To learn why the world’s top brands trust Akamai, visit www.akamai.com, blogs.akamai.com, or @Akamai on Twitter. You can find our global contact information at www.akamai.com/locations.

Akamai Contacts:
Chris Nicholson 
Media Relations 
+1 617-444-2987 
[email protected]

Tom Barth 
Investor Relations 
+1 617-274-7130 
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/telenor-myanmar-taps-akamai-for-subscriber-security-301194974.html

SOURCE Akamai Technologies, Inc.

B. Riley Financial Releases Guidance for Fourth Quarter and Full Year 2020

Q4 2020 net income guidance range of $109 to $112 million, or $4.15 to $4.27 per diluted share; Adjusted EBITDA of $175 to $180 million, and Operating adjusted EBITDA of $100 to $105 million

FY 2020 net income guidance range of $143 to $146 million, up over 75% from FY 2019, Adjusted EBITDA of $321 to $326 million, up over 55%, and Operating adjusted EBITDA of $285 to $290 million, up over 150%

Announces strategic investment in Lingo Communications

PR Newswire

LOS ANGELES, Dec. 17, 2020 /PRNewswire/ — B. Riley Financial, Inc. (NASDAQ: RILY) today released guidance for the fourth quarter and full year 2020 ending December 31, 2020.

Forecasted Fourth Quarter 2020 Results

  • Net income guidance range of $109 to $112 million, or $4.15 to $4.27 per diluted share
  • Adjusted EBITDA(1) in the range of $175 to $180 million
  • Operating adjusted EBITDA(2) in the range of $100 to $105 million

Forecasted Full Year 2020 Results

  • Net income of $143 to $146 million, or $5.19 to $5.31 per diluted share, up over 75% from FY 2019
  • Adjusted EBITDA(1) of $321 to $326 million, up over 55% from FY 2019
  • Operating adjusted EBITDA(2) of $285 to $290 million, up over 150% from FY 2019

“Our financial forecast for the fourth quarter and full year demonstrate the increasing value of our diversified platform as we continue to optimize our recurring and episodic EBITDA. Our guidance reflects the combined strength of our operating businesses which include our core investment banking, advisory services, retail liquidation, wealth management and principal investments divisions,” said Bryant Riley, Chairman and Co-Chief Executive Officer of B. Riley Financial.

“We are providing guidance in connection with recent strategic investments. This includes our investment in Lingo Communications and our recently announced investment in the Justice clothing brand – both of which we expect will result in steady cash flow generation for our platform,” added Riley.

“Our expanding platform capabilities, combined with our balance sheet flexibility, continue to provide compelling, differentiated solutions for our growing client base. We are more excited than ever about these proprietary opportunities, and we look forward to building on this year’s momentum,” said Riley.

Fourth Quarter and Full Year 2020 Guidance

For the fourth quarter of 2020, B. Riley forecasts net income to be in the range of $109 to $112 million, or $4.15 to $4.27 per diluted share. The Company’s guidance for adjusted EBITDA(1) for the quarter is in the range of $175 to $180 million, with operating adjusted EBITDA(2) in the range of $100 to $105 million. The Company forecasts investment gains of $80 million for the fourth quarter. The Company’s forecast for investment gains is dependent on financial market conditions for the remainder of the year. Investment gains include trading income and fair value adjustments on loans.

For full year 2020, the Company forecasts net income in the range of $143 to $146 million, or $5.19 to $5.31 per diluted share, with the lower end of the range up over 75% from 2019. Guidance for adjusted EBITDA(1) for the year is forecasted to be in the range of $321 to $326 million, up over 55% from 2019. Operating adjusted EBITDA(2) for the full year is expected to be in the range of $285 to $290 million, up over 150% from 2019. The Company estimates investment gains of $44 million for the full year. The Company’s forecast for investment gains for the fourth quarter and full year 2020 is dependent on financial market conditions for the remainder of the year.

Actual results for the fourth quarter and full year of 2020 may differ from these forecasts.

Summary of Recent Strategic Investments

The Company’s above guidance includes the results of the following investments only from the respective date of each such investment in the fourth quarter.

  • Justice Brand Investment: The Company recently announced it has acquired significant interest in the Justice clothing brand through an investment in Bluestar Alliance’s purchase from ascena retail group. Results for this investment will be realized in future quarters under the Brands segment, which comprises licensing revenue related to B. Riley’s interest in the intellectual property and related assets of various fashion brands.
  • Lingo Recapitalization: B. Riley Principal Investments acquired the outstanding debt of Lingo Communications (“Lingo”), converting a portion of that debt into a 40% equity ownership held by B. Riley. The first tranche of the transaction closed on November 30, 2020. The second tranche, under which B. Riley can convert additional debt for an additional 40% equity ownership stake, is expected to close in 2021, subject to receiving customary regulatory approvals. Lingo is a global Cloud/UC and managed service provider to small- and medium-sized businesses, and carrier and consumer markets around the globe. The Lingo investment aligns with the Company’s telecom and cloud vertical principal investment companies, magicJack and United Online. Lingo’s debt restructuring supports the acceleration of its strategy in the business and carrier markets, while also utilizing the Company’s financial and operational expertise to generate cash flow for the B. Riley platform. As part of the transaction, Lingo has also granted B. Riley representation on its Board.

About B. Riley Financial, Inc. (NASDAQ: RILY)

B. Riley Financial, Inc. provides collaborative financial services solutions tailored to fit the capital raising, business, operational, and financial advisory needs of its clients and partners. B. Riley operates through several subsidiaries which offer a diverse range of complementary end-to-end capabilities spanning investment banking and institutional brokerage, private wealth and investment management, corporate advisory, restructuring, due diligence, forensic accounting, litigation support, appraisal and valuation, and auction and liquidation services. Certain registered affiliates of B. Riley originate and underwrite senior secured loans for asset-rich companies. B. Riley also makes proprietary investments in companies and assets with attractive return profiles. For the latest Company news and developments, follow B. Riley on Twitter @BRileyFinancial and on LinkedIn. For more information about B. Riley and our affiliated companies, visit our website at www.brileyfin.com.

Footnotes (See “Note Regarding Use of Non-GAAP Financial Measures” for further discussion of these non-GAAP terms.)

(1) Adjusted EBITDA includes earnings before interest, taxes, depreciation, amortization, restructuring costs, share-based payments, impairment of tradenames, and transaction related and other costs. For a definition of adjusted EBITDA and a reconciliation to GAAP financial measures, please see the Appendix.

(2) Operating adjusted EBITDA is defined as adjusted EBITDA excluding trading income (losses) and fair value adjustments on loans and other investment related expenses.

Forward-Looking Statements

Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. You should not place undue reliance on such forward-looking statements, which are based on the information currently available to us and speak only as of the date of this press release. Such forward looking statements include, but are not limited to, statements regarding the Company’s anticipated results of operations for 2020, as well as statements regarding our excitement and the expected growth of our business segments. Factors that could cause such actual results to differ materially from those contemplated or implied by such forward-looking statements include, without limitation, the risks associated with the unpredictable and ongoing impact of the COVID-19 pandemic and other risks described from time to time in B. Riley Financial, Inc.’s periodic filings with the SEC, including, without limitation, the risks described in B. Riley Financial, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020 under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (as applicable). These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. All information is current as of the date this press release is issued, and B. Riley Financial, Inc. undertakes no duty to update this information.

Note Regarding Use of Non-GAAP Financial Measures

Certain of the information set forth herein, including operating revenue, adjusted EBITDA, operating adjusted EBITDA, and investment adjusted EBITDA may be considered non-GAAP financial measures. B. Riley Financial believes this information is useful to investors because it provides a basis for measuring the Company’s available capital resources, the operating performance of its business and its revenues and cash flow, (i) excluding in the case of operating revenues, trading income (losses) and fair value adjustments on loans, (ii) excluding in the case of adjusted EBITDA , net interest expense, provisions for or benefit from income taxes, depreciation, amortization, fair value adjustment, restructuring costs, impairment of trade names, stock-based compensation and transaction and other expenses, (iii) excluding in the case of operating adjusted EBITDA, aforementioned adjustments for adjusted EBITDA, trading income (losses) and fair value adjustments on loans, and other investment related expenses, and (iv) in the case of investment adjusted EBITDA this includes trading income (losses) and fair value adjustments on loans, net of other investment related expenses, that would normally be included in the most directly comparable measures calculated and presented in accordance with Generally Accepted Accounting Principles (“GAAP”). In addition, the Company’s management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measures in evaluating the Company’s operating performance, capital resources and cash flow. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-financial measures as reported by the Company may not be comparable to similarly titled amounts reported by other companies.

Contacts

Investor Relations
B. Riley Financial
[email protected] 
(818) 746-9310

Media Relations

Jo Anne McCusker

[email protected] 
(646) 885-5425


B. RILEY FINANCIAL, INC.


Reconciliation of Net Income Guidance to Adjusted EBITDA and Operating Adjusted EBITDA Guidance


(Unaudited)


(Dollars in thousands)


Guidance


Prior Period


Guidance


Prior Period


3 Months Ended
12/31/2020


3 Months Ended
12/31/2019


12 Months Ended
12/31/2020


12 Months Ended
12/31/2019


Low


High


Actual


Low


High


Actual

Net income attributable to B. Riley Financial, Inc.

$

109,000

$

112,200

$

17,129

$

142,554

$

145,754

$

81,611

Adjustments:

Provision for income taxes

40,800

42,200

7,842

54,180

55,580

34,644

Interest expense

16,200

16,400

15,075

64,737

64,937

50,205

Interest income

(100)

(100)

(248)

(637)

(637)

(1,577)

Share based payments

4,300

4,500

5,640

18,567

18,767

15,916

Depreciation and amortization

4,700

4,700

4,831

19,465

19,465

19,048

Restructuring costs  

1,557

1,557

1,699

Impairment of tradenames

12,500

12,500

Transactions related costs and other

300

300

8,609

8,609

6,339

Total EBITDA adjustments

66,200

68,000

33,140

178,978

180,778

126,274

Adjusted EBITDA

$

175,200

$

180,200

$

50,269

$

321,532

$

326,532

$

207,885

Operating EBITDA Adjustments:

Trading (income) losses and fair value adjustments on loans

(80,000)

(80,000)

(34,733)

(43,858)

(43,858)

(106,463)

Other investment related expenses

4,800

4,800

858

7,212

7,212

12,181

Total Operating EBITDA Adjustments

(75,200)

(75,200)

(33,875)

(36,646)

(36,646)

(94,282)

Operating Adjusted EBITDA

$

100,000

$

105,000

$

16,394

$

284,886

$

289,886

$

113,603



 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/b-riley-financial-releases-guidance-for-fourth-quarter-and-full-year-2020-301195006.html

SOURCE B. Riley Financial

Great Panther Restarts Operations at Topia

PR Newswire

TSX: GPR  | NYSE American: GPL

VANCOUVER, BC, Dec. 17, 2020 /PRNewswire/ – Great Panther Mining Limited (TSX: GPR) (NYSE-A: GPL) (“Great Panther” or the “Company”) has re-started operations at Topia following a voluntary suspension last month to prioritize the health of its workforce and local community and limit the spread of COVID-19.

All employees and contractors have attended safety induction and enhanced COVID-19 protocol training. Mining resumed on December 17 and the plant is expected to begin processing ore on December 21.

Testing and tracing of COVID-19 are part of the comprehensive protocols Great Panther has implemented across all of its operations in response to the pandemic. The Company will continue working closely with local government and regional health authorities to ensure continued safe operations.

The suspension of operations lasted approximately 30 days and is not expected to impact Great Panther’s ability to achieve consolidated 2020 production guidance. For the three months ended September 30, 2020, Topia produced an average of approximately 1,400 gold equivalent ounces per month and accounted for approximately 9% of the Company’s revenues.

Great Panther reaffirms its commitment to the safety of its people and the communities in which it operates.

ABOUT GREAT PANTHER

Great Panther is a growing gold and silver producer focused on the Americas. The Company owns a diversified portfolio of assets in Brazil, Mexico and Peru that includes three operating gold and silver mines, four exploration projects, and an advanced development project. Great Panther is actively exploring large land packages in highly prospective districts and is pursuing acquisition opportunities to complement its existing portfolio. Great Panther trades on the Toronto Stock Exchange trading under the symbol GPR, and on the NYSE American under the symbol GPL.

CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws (together, “forward-looking statements”). Such forward-looking statements may include, but are not limited to, statements regarding developments related to COVID-19, including the Company’s plans to restart operations at its Topia mine and commence ore processing, expectation that the suspension of the mine operations at Topia will not materially impact the Company’s ability to achieve consolidated production guidance and expectations around the potential cases of COVID-19 at the Company’s mining operations in Topia and in the community and whether we will be successful and able to continue with our efforts to protect our personnel, communities and others in respect of our business. These forward-looking statements and information reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include the assumption that the Company’s restart of operations at Topia and work with local government and regional health authorities will be successful at limiting the spread of COVID-19, that the Company will be able to safely resume and ramp-up its operations without significantly impacting the Company’s production and cost guidance and ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive.

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements expressed or implied by such forward-looking statements to be materially different. Such factors include, among others, risks and uncertainties relating to: the impact of COVID–19 on the Company’s ability to restart or ramp-up its operations and commence ore processing at Topia and the related impact of the suspension which has  adversely impact the Company’s anticipated revenues and may impact the ability to meet the Company’s production and cost guidance for Topia and the consolidated production guidance for the Company’s operations; the Company may experience delays in the restart or ramp-up of operations at Topia as a result of COVID-19, including shortages of employees and unavailability of contractors and subcontractors, interruption of supplies and the provision of services from third parties upon which the Company relies, equipment failures and restrictions that governments may impose to address the COVID-19 outbreak; there may be an increase in COVID-19 infection amongst the Company’s employees, contractors and the community, even with the adoption of the suspension and added safety protocols and safeguards, including risk of loss of life; potential political and social risks involving Great Panther’s operations in a foreign jurisdiction; the potential for unexpected costs and expenses or overruns; employee and contractor relations may be adversely impacted; relationships with, and claims by, local communities may be adversely impacted; the Company may experience changes in laws, regulations and government practices in the jurisdictions in which the Company operates, including additional environmental, healthy and safety laws; ability to maintain and renew agreements with local communities to support continued operations; and other risks and uncertainties, including those described in respect of Great Panther, in its annual information form for the year ended December 31, 2019, and material change reports filed with the Canadian Securities Administrators available at www.sedar.com and reports on Form 40-F and Form 6-K filed with the Securities and Exchange Commission and available at www.sec.gov.

There is no assurance these forward-looking statements will prove accurate or that actual results will not vary materially from these forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described, or intended. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward-looking statements and information are designed to help readers understand management’s current views of the Company’s near- and longer-term prospects and may not be appropriate for other purposes. The Company does not intend, nor does it assume any obligation to update or revise forward-looking statements or information, whether as a result of new information, changes in assumptions, future events or otherwise, except to the extent required by applicable law.

Cision View original content:http://www.prnewswire.com/news-releases/great-panther-restarts-operations-at-topia-301194642.html

SOURCE Great Panther Mining Limited

Nu Skin Honored with Multiple Awards by the Direct Selling Association

Company recognized for sustainability efforts and sales performance plan at 2020 DSA Virtual Awards Ceremony

PR Newswire

PROVO, Utah, Dec. 17, 2020 /PRNewswire/ — Nu Skin was recognized with multiple awards by the U.S. Direct Selling Association (DSA) this week at the 2020 DSA Virtual Awards Ceremony. The company’s sustainability efforts won in the Vision for Tomorrow category, and its Velocity sales performance plan won in the Excellence in Business category. Nu Skin was also recognized as part of the DSA Top 25, noting the 25 largest DSA member companies.

The annual DSA Awards recognize the exceptional programs that direct selling companies have incorporated into their business practices. Finalists were selected by a committee, and the winners were voted on by more than 1,800 individuals within DSA member companies.

“We are honored to be recognized by the DSA for our efforts in sustainability as well as our sales performance plan,” says Ryan Napierski, president. “Nu Skin is committed to embracing sustainable practices today that will enhance a more resource rich tomorrow. We also strive to be bold innovators in every corner of our business, and we’re proud to see that innovation integrated within our sales performance programs.”

Nu Skin’s sustainability commitments focus on improvements in three key, impact areas: people, planet and product. These improvements include assessing environmental impact scores, building a global network of zero-waste facilities, and investing in communities and people that are providing essential resources for our planet. The Velocity by Nu Skin sales performance plan offers fast rewards (daily and weekly pay) and empowers sales leaders with the opportunity to build their own business in a flexible, fulfilling way.

About Nu Skin
Founded more than 35 years ago, Nu Skin develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin® personal care brand, the Pharmanex® nutrition brand, and most recently, the ageLOC® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC LumiSpa skin cleansing and treatment device, ageLOC Youth nutritional supplement, the ageLOC Me® customized skin care system, as well as the ageLOC TR90® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry’s consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin International is a wholly owned subsidiary of Nu Skin Enterprises, Inc., which is traded on the New York Stock Exchange under the symbol (NYSE: NUS). More information is available at nuskin.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nu-skin-honored-with-multiple-awards-by-the-direct-selling-association-301194892.html

SOURCE Nu Skin

Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster

— Artificial intelligence-powered technology helps bring the benefits of comprehensive clinical sequencing to patient care while maintaining exceptional accuracy and reproducibility —

PR Newswire

SAN FRANCISCO, Dec. 17, 2020 /PRNewswire/ — Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine case-level reanalysis of their findings every six months for at least three years. Reanalysis ensures patients’ reports will be regularly updated based on new research about links between variants in their genes and their health — an essential step for people grappling with difficult-to-diagnose health problems.

The expanded service will draw on Invitae’s industry-leading genetic variant interpretation capabilities, which include an artificial intelligence (AI)-powered diagnosis engine and an up-to-date gene-phenotype database, and is coupled with review by a team of leading genetics experts. The combination provides accurate, reproducible, and unbiased exome interpretation. With the new reanalysis service, each patient’s genetic findings will be reanalyzed every six months so that any newly discovered and clinically relevant information can be used to help aid in diagnosis and guide proper disease management and treatment.

Invitae will be one of the only laboratories to make sequential, case-level reanalysis standard for all patients who receive exome sequencing. The American College of Medical Genetics and Genomics (ACMG) considers ongoing reanalysis of sequence data to be critical, as it can increase the number of patients receiving information that is relevant to diagnosis or care by as much as 20 percent. 

“Getting to an accurate molecular diagnosis as quickly as possible means patients can begin to receive appropriate management and therapy sooner, which is crucial, particularly in conditions for which early intervention can improve outcomes or in conditions with a significant recurrence risk to the parents of an affected child. Unfortunately, many patients go years before they are accurately diagnosed,” said Robert Nussbaum, M.D., chief medical officer of Invitae. “New information on gene-disease relationships is discovered at a rapid pace in this fast-moving field, and each additional piece of information has the potential to benefit a patient. We want to ensure our patients and their clinicians have continually updated findings so we can help shorten the diagnostic odyssey for as many patients as possible.”

Invitae’s AI-powered diagnosis engine prioritizes the most relevant variants in a patient’s exome based on next-generation sequencing genotype data and against clinical features provided by the patient. Variants are compared to a constantly updated database of gene-disease relationships, which leverages natural language processing and other technologies to continually and automatically scan scientific literature to curate the latest information on genetics and human diseases. The approach was built in part with technologies obtained in March 2020 through the acquisition of Diploid, a privately held Belgian company that developed Moon, AI software capable of diagnosing genetic disorders in minutes based on next-generation sequencing data and patient information. 

The curated information provided by the automated systems fit seamlessly within Invitae’s validated and quantitative variant classification system, which expands on ACMG/Association for Molecular Pathology guidelines to ensure consistent and reproducible evaluation of variant pathogenicity.

Learn more about Invitae’s exome sequencing offering here. A webinar, “Invitae exome interpretation: Leading with science and innovation to bring exomes to scale,” is scheduled for Tuesday, January 12, 2021 at 12:00 p.m. PT / 3:00 p.m. ET. Register for the webinar here.

About Invitae
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae’s goal is to aggregate the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company’s website at invitae.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits and capabilities of the company’s exome reanalysis service; and the benefits of updated genetic information. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s history of losses; the company’s ability to compete; the company’s failure to manage growth effectively; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company’s business; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Contact:
Laura D’Angelo
[email protected]
(628) 213-3283

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-introduces-routine-exome-reanalysis-to-help-patients-receive-diagnoses-faster-301194780.html

SOURCE Invitae Corporation

Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

PR Newswire

HOUSTON, Dec. 17, 2020 /PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the company’s Investigational New Drug (IND) application to study Annamycin for the treatment of soft tissue sarcoma lung metastases to go into effect.  This allows Moleculin to begin a Phase 1B/2 clinical trial in the US for patients with soft tissue sarcoma that has metastasized to the lungs after first-line therapy for their disease. 

It is estimated that there are approximately 36,000 new cases of soft tissue sarcoma (STS) in the 7 major markets (US, EU5 and Japan) each year, and an estimated annual market size of over $177 million for the treatment of STS lung metastases.  Our clinical advisors estimate that approximately half of all STS patients will eventually develop lung metastases from their primary tumor.  Although first-line treatments such as surgical resection, chemotherapy and radiation may provide initial therapeutic benefit for an estimated 35% of those patients, there are no approved or emerging second-line therapies for the remaining 65% who relapse or are refractory.  Although the lungs tend to be a major site of relapse, we are aware of only 2 active clinical trials specifically targeting STS lung metastases, indicating that Annamycin faces limited competition in this area of development.

Moleculin recently announced that Annamycin demonstrates consistently high antitumor activity in vivo in all tested animal models of different types of lung-localized cancers, including sarcoma. These promising findings correlate with surprisingly high uptake of Annamycin to the lungs in animal models. This uptake is up to 34-fold higher than that of doxorubicin, the primary first-line chemotherapy for STS.  The limited pulmonary uptake of doxorubicin in animal models may help explain its lack of activity against STS lung metastases in humans.  Additionally, clinical data show no cardiotoxicity associated with the use of Annamycin, as well as the ability to avoid multidrug resistance mechanisms, both of which are often treatment-limiting effects of anthracyclines (which includes doxorubicin) in this setting.   Taken together, these factors suggest that Annamycin could represent an important treatment to help address a significant unmet need in patients with STS lung metastases. 

“Since the discovery in animal models of Annamycin’s effectiveness in lung metastases, we have been moving quickly to begin a clinical trial in the US to study Annamycin for this indication,” commented Walter Klemp, Chairman and CEO of Moleculin. “Recognizing the importance of building on the results with human clinical data, we preemptively included this upcoming trial as part of our budget plan, so our anticipated cash runway into the third quarter of 2021 remains unchanged. We are also collaborating with our partners and physicians in Poland who have shown a high level of interest in testing Annamycin in STS lung metastases and are currently pursuing a possible investigator-led clinical trial in Europe.  It is our goal to have to have our US clinical trial begin by mid-2021, with the possibility of also initiating a European investigator-funded clinical trial in 2021.”

Mr. Klemp concluded: “Along with the results in STS lung metastases, our animal models have shown significant activity in other lung metastases, including colorectal and triple negative breast cancer, as well as meaningful concentration levels of Annamycin in the liver, spleen and pancreas.  Additionally, when tested in a highly aggressive AML mouse model, Annamycin significantly reduced tumor burden in the spleen, lungs and liver, leading to a significant increase in survival.  Based on this promising preclinical data, we believe the ultimate market opportunity for Annamycin could be much larger than just STS lung metastases.  For all these reasons, we are excited to be moving from the animal models to clinical study.”

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors and viruses. The Company’s clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Company to begin a clinical trial in the US by mid-2021 or the ability of an Investigator-funded trial to begin in Europe during 2021, the ability of Annamycin to demonstrate safety and efficacy in patients, and the Company’s estimated cash runway. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC.  Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts

James Salierno / Carol Ruth
The Ruth Group
973-255-8361 / 917-859-0214
[email protected]
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-fda-permission-to-begin-clinical-study-of-annamycin-for-sarcoma-lung-metastases-301194951.html

SOURCE Moleculin Biotech, Inc.

Aramark Nominates Bridgette Heller to Board of Directors

Aramark Nominates Bridgette Heller to Board of Directors

PHILADELPHIA–(BUSINESS WIRE)–
Aramark (NYSE:ARMK), a global leader in food, facilities management and uniforms, announced today that Bridgette Heller has been nominated for election to the Company’s Board of Directors at its annual meeting of shareholders to be held on February 2, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005301/en/

Bridgette Heller, a highly respected global business leader with 35 years of experience in food, health & wellness and consumer care, has been nominated for election to Aramark's Board of Directors at its annual meeting of shareholders to be held on February 2, 2021. (Photo: Business Wire)

Bridgette Heller, a highly respected global business leader with 35 years of experience in food, health & wellness and consumer care, has been nominated for election to Aramark’s Board of Directors at its annual meeting of shareholders to be held on February 2, 2021. (Photo: Business Wire)

A highly respected global business leader with 35 years of experience in food, health & wellness and consumer care, Heller most recently served as the President of Nutricia, the Specialized Nutrition Division of Danone.

During her tenure, Heller’s organization achieved industry-leading growth and profitability, while simultaneously championing diversity and inclusion. From 2010-2015, Heller served as Executive Vice President of Merck & Co. and President of Merck Consumer Care. Prior to joining Merck, she was President of Johnson & Johnson’s Global Baby Business Unit. Heller began her career at Kraft Foods, where she spent 17 years, ultimately serving as Executive Vice President and General Manager for the North American Coffee Portfolio.

“Bridgette is a prominent corporate leader with an extremely impressive track record of accelerating growth at several Fortune 100 Most Admired Companies,” said Steve Sadove, Aramark’s Chairman of the Board. “We are thrilled for the opportunity to have Bridgette join the Board as an additional independent director and leverage her extensive value-creating experiences as Aramark’s transformative actions across the business are realized.”

Heller is the Founder and Chief Executive Officer of the Shirley Proctor Puller Foundation, a non-profit organization with a mission of advancing achievement and closing the achievement gap for underserved students in Florida. She holds an MBA from Northwestern University’s Kellogg Graduate School of Management, and a bachelor’s degree in Economics and Computer Science from Northwestern University, where she is a member of the school’s Advisory Board. Heller serves on the Board of Directors for public companies Novartis and DexCom. In August 2020, Heller was also appointed to the Board of Directors for Newman’s Own, the food and beverage company that was created by Paul Newman with a commitment to charitable contribution.

Following Heller’s election by Aramark’s shareholders at the 2021 Annual Meeting and the election of the other director nominees, the Aramark Board will consist of twelve members.

About Aramark

Aramark (NYSE: ARMK) proudly serves the world’s leading educational institutions, Fortune 500 companies, world champion sports teams, prominent healthcare providers, iconic destinations and cultural attractions, and numerous municipalities in 19 countries around the world. We deliver innovative experiences and services in food, facilities management and uniforms to millions of people every day. We strive to create a better world by making a positive impact on people and the planet, including commitments to engage our employees; empower healthy consumers; build local communities; source ethically, inclusively and responsibly; operate efficiently and reduce waste. Aramark is recognized as a Best Place to Work by the Human Rights Campaign (LGBTQ+), DiversityInc, Equal Employment Publications and the Disability Equality Index. Learn more at www.aramark.com or connect with us on Facebook and Twitter.

Important Information

Aramark intends to file a definitive proxy statement and proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its solicitation of proxies for Aramark‘s 2021 Annual Meeting of stockholders (the “Proxy Statement” and such meeting the “2021 Annual Meeting”). Aramark, its directors, director nominees and certain of its executive officers may be deemed participants in the solicitation of proxies from stockholders in respect of the 2021 Annual Meeting. Information regarding the names of Aramark’s directors, director nominees and executive officers and their respective interests in Aramark is contained herein or is set forth in Aramark‘s proxy statement for the 2020 Annual Meeting of stockholders, filed with the SEC on December 20, 2019 (the “2020 Proxy Statement”) and additional solicitation materials filed with the SEC related thereto. Information regarding the ownership of Aramark’s directors and executive officers in Aramark stock is included in their SEC filings on Forms 3, 4 and 5, which can be found through the SEC’s website at www.sec.gov. Additional information can also be found in Aramark’s Annual Report on Form 10-K for the fiscal year ended October 2, 2020, filed with the SEC on November 24, 2020. Details concerning the nominees of Aramark’s Board of Directors for election at the 2021 Annual Meeting and more detailed and updated information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement (and any amendments and supplements thereto) to be filed with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF ARAMARK ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING ARAMARK’S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents, including the Proxy Statement (and any amendments or supplements thereto) and other documents filed by Aramark with the SEC are available for no charge at the SEC’s website at http://www.sec.gov. Copies may also be obtained by contacting Aramark Investor Relations by mail at 2400 Market Street, Philadelphia, Pennsylvania 19103, Attention: Investor Relations.

Investor Inquiries

Felise Kissell

215-409-7287

[email protected]

Media Inquiries

David Freireich

215-238-4078

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Retail Other Professional Services Professional Services Food/Beverage

MEDIA:

Logo
Logo
Photo
Photo
Bridgette Heller, a highly respected global business leader with 35 years of experience in food, health & wellness and consumer care, has been nominated for election to Aramark’s Board of Directors at its annual meeting of shareholders to be held on February 2, 2021. (Photo: Business Wire)

BWXT Names Former Chief of Naval Operations Adm. John M. Richardson to Board of Directors

BWXT Names Former Chief of Naval Operations Adm. John M. Richardson to Board of Directors

LYNCHBURG, Va.–(BUSINESS WIRE)–
BWX Technologies, Inc. (NYSE: BWXT) announced today that retired Adm. John M. Richardson has been appointed to its board of directors.

Adm. Richardson served as the Chief of Naval Operations for the U.S. Navy from 2015 to 2019 and as Director of the Naval Nuclear Propulsion Program from 2012 to 2015. As Chief of Naval Operations, he was responsible for the management of a $160 billion budget covering 600,000 sailors and civilians, more than 70 installations, 290 warships and more than 2,000 aircraft worldwide.

During his 37 years of service in the U.S. Navy, Adm. Richardson gained valuable operational and national security experience, including responsibility for ensuring the safe, reliable and long-lived operation of naval nuclear reactors for the U.S. Navy’s fleet. He also served on four nuclear submarines, including commanding the submarine USS Honolulu.

“Given his impeccable national security credentials and broad executive skill set, Admiral Richardson is exceptionally well suited to join our board,” said John A. Fees, chairman of BWXT. “He has a deep understanding of our business given his previous U.S. Navy roles, and BWXT will greatly benefit from his experience and counsel moving forward.”

Adm. Richardson earned a bachelor’s degree in physics from the U.S. Naval Academy, a master’s degree in electrical engineering from the Massachusetts Institute of Technology and Woods Hole Oceanographic Institution and a master’s degree in National Security Strategy from the National War College.

He also serves on the Board of Directors of The Boeing Company and Exelon Corporation.

About BWXT

At BWX Technologies, Inc. (NYSE: BWXT), we are People Strong, Innovation Driven. Headquartered in Lynchburg, Va., BWXT provides safe and effective nuclear solutions for national security, clean energy, environmental remediation, nuclear medicine and space exploration. With approximately 6,700 employees, BWXT has 12 major operating sites in the U.S. and Canada. In addition, BWXT joint ventures provide management and operations at more than a dozen U.S. Department of Energy and NASA facilities. Follow us on Twitter at @BWXTech and learn more at www.bwxt.com.

Media Contact

Jud Simmons

Director, Media & Public Relations

434-522-6462

[email protected]

Investor Contact

Mark Kratz

Director, Investor Relations

980.365.4300

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Security Defense Technology Energy Nuclear Other Defense

MEDIA:

Logo
Logo

Sanderson Farms, Inc. Reports Results for Fourth Quarter and Fiscal 2020

Sanderson Farms, Inc. Reports Results for Fourth Quarter and Fiscal 2020

LAUREL, Miss.–(BUSINESS WIRE)–
Sanderson Farms, Inc. (NASDAQ: SAFM) today reported results for the fourth quarter and fiscal year ended October 31, 2020.

Net sales for the fourth quarter of fiscal 2020 were $940.0 million compared with $906.5 million for the same period a year ago. For the quarter, the Company reported net income of $27.9 million, or $1.26 per share, compared with a net loss of $22.9 million, or $1.05 per share, for the fourth quarter of fiscal 2019.

Net sales for fiscal 2020 were $3.564 billion compared with $3.440 billion for fiscal 2019. Net income for the fiscal year totaled $28.3 million, or $1.27 per share, compared with net income of $53.3 million, or $2.41 per share, for last fiscal year.

“Over the course of the fourth quarter and fiscal year ended October 31, 2020, our company and industry faced extraordinary challenges caused by the COVID-19 pandemic and the unprecedented social and economic impact the virus continues to have on the United States,” said Joe F. Sanderson, chairman and chief executive officer of Sanderson Farms, Inc. “Through our diligent efforts to implement protocols designed to keep our teams and communities safe, and our ability to shift our production to the highest demand areas, our operations have continued to perform well and have helped to feed American families and maintain the U.S. food supply during the pandemic. I must thank our employees, our contract poultry producers, our customers, our vendors, the consumers who buy our products and the communities and states in which we operate for their hard work, dedication and perseverance during these unprecedented times. I am so very grateful for everyone associated with Sanderson Farms for rising to the challenges of 2020.

“While demand from our food service customers has remained under pressure, demand for chicken products sold to retail grocery store customers remained strong through the end of the fiscal year. We believe these conditions will continue until consumers return to restaurants and resume dining away from home in large numbers. Therefore, we are continuing to shift our production toward the tray packs that are in high demand in the retail grocery market.”

Sanderson continued, “We are confident in our ability to continue to execute our organic growth strategy and enhance value for our shareholders and other stakeholders. As such, our Board of Directors recently increased our cash dividend and extended our share repurchase plan.

“For the fiscal year, we reported record volume of poultry products sold of 4.81 billion pounds, compared to 4.53 billion pounds in fiscal 2019. Grain prices were slightly lower during fiscal 2020 compared with prices paid in fiscal 2019, and feed costs in processed flocks were lower by 3.4 percent.”

According to Sanderson, overall realized prices for poultry products were 0.4 percent lower in fiscal 2020 compared with prices last year. Boneless breast meat market prices averaged 2.8 percent higher in the fourth quarter than the prior-year period. For the full fiscal year, boneless breast meat market prices were 4.3 percent lower compared with fiscal 2019. Jumbo wing market prices averaged $1.89 per pound during the fourth quarter of fiscal 2020, up 9.0 percent from the average of $1.73 per pound during the prior-year period. Jumbo wing market prices averaged $1.61 per pound during the fiscal year, down 6.6 percent from the average of $1.72 per pound for fiscal 2019. The average market price for bulk leg quarters decreased approximately 42.8 percent for the fourth fiscal quarter of 2020 compared with the fourth fiscal quarter of 2019, and decreased 20.6 percent for fiscal 2020 compared to fiscal 2019. Cash prices for corn during the fourth fiscal quarter decreased by 15.2 percent, while soybean meal cash prices were higher by 4.7 percent. For the full fiscal year, cash corn prices were lower by 3.8 percent, and soymeal cash prices were lower by 0.5 percent when compared to fiscal 2019.

“Prices paid for feed grain during fiscal 2020 were lower when compared to fiscal 2019, representing the eighth straight year of relatively flat or lower grain costs. However, we expect feed grain costs to increase in fiscal 2021. The USDA has lowered 2020 corn and soybean crop yield estimates and has increased its estimate of export demand. As a result, market prices for both corn and soybeans have moved significantly higher since September. If we priced all our remaining fiscal 2021 feed grain needs at current prices, costs for corn and soybean meal during fiscal 2021 would be $193.2 million higher than during fiscal 2020, based on fiscal 2020 volumes. However, we have priced only one week’s supply of our January soybean meal needs and have not priced any other grain needs past December 31, 2020.

“As of October 31, 2020, our balance sheet reflected $1.85 billion in assets, stockholders’ equity of $1.42 billion and net working capital of $354.0 million. We believe our balance sheet provides us with the financial strength to both support our organic growth strategy and consistently manage our operations through the cycles that characterize our industry. We continue to evaluate a new site as part of our next phase of organic growth, and we hope to be in a position to announce the location and begin work on a new poultry complex during the first half of calendar 2021,” Sanderson concluded.

Sanderson Farms will hold a conference call to discuss this press release today, December 17, 2020, at 10:00 a.m. Central, 11:00 a.m. Eastern. Investors will have the opportunity to listen to a live internet broadcast of the conference call through the Company’s website at www.sandersonfarms.com. To listen to the live call, please go to the website at least 15 minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, an internet replay will be available shortly after the call and continue for 30 days. Those who wish to participate in the call may do so by dialing 866-524-3160 (ask to be joined into the Sanderson Farms, Inc. call).

Sanderson Farms, Inc. is engaged in the production, processing, marketing and distribution of fresh, frozen and minimally prepared chicken. Its shares trade on the NASDAQ Global Select Market under the symbol SAFM.

This press release includes forward-looking statements within the meaning of the “safe harbor” provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on a number of assumptions about future events and are subject to various risks, uncertainties and other factors that may cause actual results to differ materially from the views, beliefs, projections and estimates expressed in such statements. These risks, uncertainties and other factors include, but are not limited to those discussed under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended October 31, 2020, and the following:

(1) Changes in the market price for the Company’s finished products and feed grains, both of which may fluctuate substantially and exhibit cyclical characteristics typically associated with commodity markets.

(2) Changes in economic and business conditions, monetary and fiscal policies or the amount of growth, stagnation or recession in the global or U.S. economies, any of which may affect the value of inventories, the collectability of accounts receivable or the financial integrity of customers, and the ability of the end user or consumer to afford protein.

(3) Changes in the political or economic climate, trade policies, laws and regulations or the domestic poultry industry of countries to which the Company or other companies in the poultry industry ship product, and other changes that might limit the Company’s or the industry’s access to foreign markets.

(4) Changes in laws, regulations, and other activities in government agencies and similar organizations applicable to the Company and the poultry industry and changes in laws, regulations and other activities in government agencies and similar organizations related to food safety.

(5) Various inventory risks due to changes in market conditions including, but not limited to, the risk that market values of live and processed poultry inventories might be lower than the cost of such inventories, requiring a downward adjustment to record the value of such inventories at the lower of cost or net realizable value as required by generally accepted accounting principles.

(6) Changes in and effects of competition, which is significant in all markets in which the Company competes, and the effectiveness of marketing and advertising programs.The Company competes with regional and national firms, some of which have greater financial and marketing resources than the Company.

(7) Changes in accounting policies and practices adopted voluntarily by the Company or required to be adopted by accounting principles generally accepted in the United States.

(8) Disease outbreaks affecting the production, performance and/or marketability of the Company’s poultry products, or the contamination of its products.

(9) Changes in the availability and cost of labor and growers.

(10) The loss of any of the Company’s major customers.

(11) Inclement weather that could hurt Company flocks or otherwise adversely affect its operations, or changes in global weather patterns that could affect the supply and price of feed grains.

(12) Failure to respond to changing consumer preferences and negative or competitive media campaigns.

(13) Failure to successfully and efficiently start up and run a new plant or integrate any business the Company might acquire.

(14) Unfavorable results from currently pending litigation and proceedings, or litigation and proceedings that could arise in the future.

(15) Changes resulting from the COVID-19 pandemic, which could exacerbate any of the risks described above, and could include: high absentee rates that have prevented and may continue to prevent the Company from running some of its facilities at full capacity, or could in the future cause facility closures; an inability of contract poultry producers to manage their flocks; supply chain disruptions for feed grains; further changes in customer orders due to shifting consumer patterns; disruptions in logistics and the distribution chain for the Company’s products; liquidity challenges; and a continued or worsening decline in global commercial activity, among other unfavorable conditions.

Readers are cautioned not to place undue reliance on forward-looking statements made by or on behalf of Sanderson Farms. Each such statement speaks only as of the day it was made. The Company undertakes no obligation to update or to revise any forward-looking statements.The factors described above cannot be controlled by the Company. When used in this press release or in the related conference call, the words “believes”, “estimates”, “plans”, “expects”, “should”, “outlook”, and “anticipates” and similar expressions as they relate to the Company or its management are intended to identify forward-looking statements. Examples of forward-looking statements include statements of the Company’s belief about its future growth plans, future demand for its products, future prices for feed grains, future expenses, future production levels, future earnings, economic conditions or other industry conditions.

SANDERSON FARMS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

 
 
Three Months Ended
October 31,
Twelve Months Ended
October 31,

2020

2019

2020 (1)

2019 (1)

Net sales

$

940,023

 

$

906,489

 

$

3,564,267

 

$

3,440,258

 

Cost and expenses:
Cost of sales

 

848,307

 

 

884,946

 

 

3,370,111

 

 

3,158,323

 

Live inventory adjustment

 

 

 

2,800

 

 

 

 

2,800

 

Selling, general and administrative

 

49,461

 

 

51,150

 

 

205,750

 

 

211,141

 

 

897,768

 

 

938,896

 

 

3,575,861

 

 

3,372,264

 

Operating income (loss)

 

42,255

 

 

(32,407

)

 

(11,594

)

 

67,994

 

Other income (expense)
Interest income

 

16

 

 

 

 

482

 

 

 

Interest expense

 

(715

)

 

(982

)

 

(5,207

)

 

(4,156

)

Other

 

1

 

 

3

 

 

8

 

 

9

 

 

(698

)

 

(979

)

 

(4,717

)

 

(4,147

)

Income (loss) before income taxes

 

41,557

 

 

(33,386

)

 

(16,311

)

 

63,847

 

Income tax expense (benefit)

 

13,635

 

 

(10,515

)

 

(44,585

)

 

10,553

 

Net income (loss)

$

27,922

 

$

(22,871

)

$

28,274

 

$

53,294

 

 
Earnings (loss) per share:
Basic

$

1.26

 

$

(1.05

)

$

1.27

 

$

2.41

 

Diluted

$

1.26

 

$

(1.05

)

$

1.27

 

$

2.41

 

Dividends per share

$

0.44

 

$

0.32

 

$

1.40

 

$

1.28

 

 

(1)

The Condensed Consolidated Statements of Operations for the twelve months ended October 31, 2020 and 2019 were derived from the audited consolidated financial statements for those periods, but do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements.

SANDERSON FARMS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands)

 
October 31,

2020 (1)

2019 (1)

Assets
Current assets:
Cash and cash equivalents

$

49,061

 

$

95,417

 

Accounts receivable, net

 

147,546

 

 

131,778

 

Receivable from insurance companies

 

 

 

445

 

Inventories

 

290,007

 

 

289,928

 

Refundable income taxes

 

33,977

 

 

6,612

 

Prepaid expenses

 

57,544

 

 

56,931

 

Total current assets

 

578,135

 

 

581,111

 

Property, plant and equipment, net

 

1,224,746

 

 

1,185,860

 

Right-of-use assets

 

40,785

 

 

 

Other assets

 

5,365

 

 

7,163

 

Total assets

$

1,849,031

 

$

1,774,134

 

 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

$

111,463

 

$

132,741

 

Accrued expenses

 

98,663

 

 

82,940

 

Lease liabilities

 

13,981

 

 

 

Total current liabilities

 

224,107

 

 

215,681

 

Long-term debt, less current maturities

 

25,000

 

 

55,000

 

Claims payable and other liabilities

 

12,175

 

 

11,646

 

Deferred income taxes

 

141,672

 

 

74,132

 

Long-term lease liabilities

 

26,804

 

 

 

Commitments and contingencies
Stockholders’ equity:
Common stock

 

22,251

 

 

22,204

 

Paid-in capital

 

90,420

 

 

86,010

 

Retained earnings

 

1,306,602

 

 

1,309,461

 

Total stockholders’ equity

 

1,419,273

 

 

1,417,675

 

Total liabilities and stockholders’ equity

$

1,849,031

 

$

1,774,134

 

(1)

The Condensed Consolidated Balance Sheets at October 31, 2020 and 2019 were derived from the audited consolidated financial statements at those dates, but do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements.

 

Mike Cockrell

Treasurer & Chief Financial Officer

& Chief Legal Officer

(601) 426-1454

KEYWORDS: United States North America Mississippi

INDUSTRY KEYWORDS: Retail Agriculture Natural Resources Food/Beverage

MEDIA:

Logo
Logo